Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : Announcement from Biovica International's extra general meeting

10/12/2021 | 07:36am EST

The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 12 October 2021 and the following resolutions were passed by the meeting.

ELECTION OF THE BOARD OF DIRECTORS
The extra general meeting resolved that the board of directors shall consist of eight directors without deputy directors.

It was resolved that the proposed director shall be entitled to a fee of SEK 183,000.

Annika Carlsson Berg was elected as new director for the period until the end of the next annual general meeting. The current directors shall remain.

More information regarding the directors can be found on the Company's website and in the annual report for 2020/2021.

INCENTIVE PROGRAM TO NEWLY ELECTED DIRECTOR
The extra general meeting resolved, in accordance with a shareholder's proposal, to establish an incentive program through issuance of a maximum of 25,000 warrants, following which the Company's share capital may increase by no more than SEK 1,666.67. The incentive program is offered to the newly elected director through issuance of warrants to Biovica Services AB (the "Subsidiary") with subsequent transfer to the director. The warrants shall entitle to subscription of new B shares in the Company.

The Subsidiary has the right to subscribe for warrants without consideration and the director have the right to subscribe for warrants at a price equal to the warrant's market value, which shall be calculated according to the Black & Scholes valuation model.

Each warrant entitles to subscription of one (1) new B share in the Company during the period from 1 September 2025 up to an including 31 October 2025.

The subscription price shall be determined to an amount equal to 150 percent of the volume weighted average price at Nasdaq First North Premier Growth Market during the period from 28 September 2021 up to and including 11 October 2021.

In case all warrants issued under incentive program are exercised for subscription of new shares, the number of shares and votes in the Company will increase with 25,000 (with reservation for any re-calculation in accordance with the warrant terms and conditions), which corresponds to a dilution of approximately 0.08 percent of the Company's share capital and votes.

The complete terms and conditions for the warrants of incentive program and more information regarding the incentive program is available at the Company's website.

Information regarding all the Company's previous incentive programs can be found in the annual report 2020/2021 and on the Company's website.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
12/01Biovica International
AQ
12/01Q2 Interim report - Promising results published at ESMO
AQ
12/01Biovica International AB Reports Earnings Results for the Second Quarter and Six Months..
CI
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
AQ
11/24Biovica announces the start of the TK IMPACT trial at Washington University of St Louis
CI
11/19Biovica International
AQ
11/19Biovica's DiviTum«TKa in three studies at SABCS 2021
AQ
11/19Biovica International AB Announces Results from Three Different Studies Using Divitum?T..
CI
11/16Biovica International
AQ
11/16Biovica's DiviTum«TKa results published in Journal of Medical Economics
AQ
More news
Financials
Sales 2022 48,6 M 5,31 M 5,31 M
Net income 2022 -32,6 M -3,55 M -3,55 M
Net cash 2022 252 M 27,5 M 27,5 M
P/E ratio 2022 -35,3x
Yield 2022 -
Capitalization 1 015 M 111 M 111 M
EV / Sales 2022 15,7x
EV / Sales 2023 4,90x
Nbr of Employees 24
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 35,65 SEK
Average target price 103,00 SEK
Spread / Average Target 189%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors